Key Points
- Director Daniel Hancock sold 74,379 CryoPort shares at an average of $20.21, worth about $1.50 million, under a pre-arranged Rule 10b5-1 plan. The sale reduced his stake by 51.86%, leaving him with 69,052 shares.
- CryoPort reported quarterly revenue of $50.22 million, above estimates, but its loss of $0.25 per share was wider than analysts’ expected $0.18 loss.
- Analyst sentiment was generally positive: seven analysts rated the stock Buy and two Hold, for a “Moderate Buy” consensus and an average target price of $21.69.
CryoPort, Inc. (NASDAQ:CYRX - Get Free Report) Director Daniel Hancock sold 74,379 shares of the business's stock in a transaction on Monday, November 9th. The shares were sold at an average price of $20.21, for a total transaction of $1,503,199.59. Following the transaction, the director owned 69,052 shares in the company, valued at $1,395,540.92. The trade was a 51.86% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
CryoPort Stock Down 2.2%
Shares of NASDAQ CYRX opened at $20.10 on Friday. The firm has a market cap of $1.02 billion, a PE ratio of -20.72 and a beta of 1.89. CryoPort, Inc. has a 12-month low of $7.61 and a 12-month high of $21.78. The company's fifty day simple moving average is $17.35 and its 200 day simple moving average is $13.65.
CryoPort (NASDAQ:CYRX - Get Free Report) last posted its quarterly earnings results on Thursday, November 5th. The company reported ($0.25) EPS for the quarter, missing analysts' consensus estimates of ($0.18) by ($0.07). CryoPort had a negative return on equity of 8.28% and a negative net margin of 21.46%. The company had revenue of $50.22 million during the quarter, compared to analyst estimates of $48.66 million. On average, equities analysts predict that CryoPort, Inc. will post -0.88 earnings per share for the current year.
Analyst Ratings Changes
A number of equities analysts have recently issued reports on CYRX shares. KeyCorp increased their price objective on shares of CryoPort from $17.00 to $20.00 and gave the stock an "overweight" rating in a research report on Friday, November 6th. Robert W. Baird set a $26.00 target price on CryoPort in a research report on Tuesday, October 13th. Guggenheim boosted their target price on CryoPort from $16.00 to $19.00 and gave the company a "buy" rating in a research report on Thursday, October 1st. Weiss Ratings raised CryoPort from a "sell (d)" rating to a "hold (c-)" rating in a research note on Thursday, October 8th. Finally, BTIG Research increased their price target on CryoPort from $25.00 to $26.00 and gave the stock a "buy" rating in a report on Tuesday, October 13th. Seven research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $21.69.
Read Our Latest Stock Analysis on CryoPort
Institutional Trading of CryoPort
Several hedge funds have recently bought and sold shares of CYRX. Wellington Management Group LLP bought a new stake in CryoPort during the 2nd quarter valued at $8,398,000. Royce & Associates LP bought a new position in shares of CryoPort in the third quarter valued at $7,073,000. Squarepoint Ops LLC lifted its stake in shares of CryoPort by 685.1% in the second quarter. Squarepoint Ops LLC now owns 368,424 shares of the company's stock valued at $5,784,000 after buying an additional 321,497 shares in the last quarter. Russell Investments Group Ltd. grew its holdings in shares of CryoPort by 376.7% during the third quarter. Russell Investments Group Ltd. now owns 399,047 shares of the company's stock valued at $6,943,000 after buying an additional 315,343 shares during the last quarter. Finally, Bank of New York Mellon Corp acquired a new position in shares of CryoPort during the second quarter valued at about $3,363,000. Institutional investors and hedge funds own 92.90% of the company's stock.
CryoPort Company Profile
(
Get Free Report)
Cryoport, Inc. provides temperature-controlled supply chain services for the life sciences industry. Its offerings support the development and commercial distribution of cell and gene therapies, biologics, reproductive medicine products and other temperature-sensitive materials. The company's services include specialized shipping systems and packaging, transportation management, cryogenic storage, shipment monitoring and logistics support. These solutions are designed to help customers maintain required conditions and manage the handling of sensitive materials across clinical and commercial supply chains.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
